As of June 30, 2026, the Company had cash and cash equivalents, short-term deposits and restricted deposits of $104.8 million, compared to $76.9 million at December 31, 2025.
[color=rgb(235, 61, 76)]Expected Upcoming Milestone Targets:[/color]
Completion of patient recruitment in IMPACT pancreatic cancer pilot study in the U.S. in Q3 2026 , with initial data targeted for late 2026 or early 2027. For more information, please see here: https://www.clinicaltrials.gov/study/NCT0669845
Completion of patient recruitment in REGAIN recurrent GBM trial in the U.S. in the second half of 2026 , with additional data expected to be released by around the end of 2026. For more information, please see here: https://clinicaltrials.gov/study/NCT06910306
First patient treated in U.S. locally recurrent prostate cancer pilot trial in the second half of 2026 . For more information, please see here: https://clinicaltrials.gov/study/NCT07290998
Top-line data in the ReSTART pivotal U.S. multi-center trial in recurrent cutaneous squamous cell carcinoma in late 2026 or early 2027. For more information, please see here: https://www.clinicaltrials.gov/study/NCT05323253
We have been receiving myriad inbounds from academic and medical centers around the world, expressing interest in exploring Alpha DaRT in treating an ever broader list of cancer indications, and with that input we have identified the next key indications that will keep us busy in the coming months.
https://alphatau.com/alpha-tau-announces-seco...te-update/
[color=rgb(235, 61, 76)]Expected Upcoming Milestone Targets:[/color]
Completion of patient recruitment in IMPACT pancreatic cancer pilot study in the U.S. in Q3 2026 , with initial data targeted for late 2026 or early 2027. For more information, please see here: https://www.clinicaltrials.gov/study/NCT0669845
Completion of patient recruitment in REGAIN recurrent GBM trial in the U.S. in the second half of 2026 , with additional data expected to be released by around the end of 2026. For more information, please see here: https://clinicaltrials.gov/study/NCT06910306
First patient treated in U.S. locally recurrent prostate cancer pilot trial in the second half of 2026 . For more information, please see here: https://clinicaltrials.gov/study/NCT07290998
Top-line data in the ReSTART pivotal U.S. multi-center trial in recurrent cutaneous squamous cell carcinoma in late 2026 or early 2027. For more information, please see here: https://www.clinicaltrials.gov/study/NCT05323253
We have been receiving myriad inbounds from academic and medical centers around the world, expressing interest in exploring Alpha DaRT in treating an ever broader list of cancer indications, and with that input we have identified the next key indications that will keep us busy in the coming months.
https://alphatau.com/alpha-tau-announces-seco...te-update/
